Cargando…
Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure
Background: Heart Failure (HF), a leading cause of morbidity and mortality, represents a relevant trigger for the development of frailty in the elderly. Inflammation has been reported to play an important role in HF and frailty pathophysiology. Galectin-3 (Gal-3), whose levels increase with aging, e...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408835/ https://www.ncbi.nlm.nih.gov/pubmed/32674344 http://dx.doi.org/10.3390/jcm9072229 |
_version_ | 1783567924191035392 |
---|---|
author | Komici, Klara Gnemmi, Isabella Bencivenga, Leonardo Vitale, Dino Franco Rengo, Giuseppe Di Stefano, Antonino Eleuteri, Ermanno |
author_facet | Komici, Klara Gnemmi, Isabella Bencivenga, Leonardo Vitale, Dino Franco Rengo, Giuseppe Di Stefano, Antonino Eleuteri, Ermanno |
author_sort | Komici, Klara |
collection | PubMed |
description | Background: Heart Failure (HF), a leading cause of morbidity and mortality, represents a relevant trigger for the development of frailty in the elderly. Inflammation has been reported to play an important role in HF and frailty pathophysiology. Galectin-3 (Gal-3), whose levels increase with aging, exerts a relevant activity in the processes of cardiac inflammation and fibrosis. The aim of the present study was to investigate the potential of Galectin-3 to serve as a biomarker of frailty in HF patients. Methods: 128 consecutive patients aged 65 and older with the diagnosis of systolic HF underwent a frailty assessment and blood sample collection for serum Gal-3 detection. A multivariable regression analysis and decision curve analysis (DCA) were used to identify significant predictors of frailty. Results: Frailty was present in 42.2% of patients. Age: Odds Ratio (OR) = 3.29; 95% Confidence Interval CI (CI) = 1.03–10.55, Cumulative Illness Rating Scale Comorbidity Index (CIRS-CI): OR = 1.85; 95% CI = 1.03–3.32, C-Reactive phase Protein (CRP) OR = 3.73; 95% CI = 1.24–11.22, N-terminal-pro-Brain Natriuretic Peptide (NT-proBNP): OR = 2.39; 95% CI = 1.21–4.72 and Gal-3: OR = 5.64; 95% CI = 1.97–16.22 resulted in being significantly and independently associated with frailty. The DCA demonstrated that the addition of Gal-3 in the prognostic model resulted in an improved clinical ‘net’ benefit. Conclusions: Circulating levels of Gal-3 are independently associated with frailty in elderly patients with systolic HF. |
format | Online Article Text |
id | pubmed-7408835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74088352020-08-13 Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure Komici, Klara Gnemmi, Isabella Bencivenga, Leonardo Vitale, Dino Franco Rengo, Giuseppe Di Stefano, Antonino Eleuteri, Ermanno J Clin Med Article Background: Heart Failure (HF), a leading cause of morbidity and mortality, represents a relevant trigger for the development of frailty in the elderly. Inflammation has been reported to play an important role in HF and frailty pathophysiology. Galectin-3 (Gal-3), whose levels increase with aging, exerts a relevant activity in the processes of cardiac inflammation and fibrosis. The aim of the present study was to investigate the potential of Galectin-3 to serve as a biomarker of frailty in HF patients. Methods: 128 consecutive patients aged 65 and older with the diagnosis of systolic HF underwent a frailty assessment and blood sample collection for serum Gal-3 detection. A multivariable regression analysis and decision curve analysis (DCA) were used to identify significant predictors of frailty. Results: Frailty was present in 42.2% of patients. Age: Odds Ratio (OR) = 3.29; 95% Confidence Interval CI (CI) = 1.03–10.55, Cumulative Illness Rating Scale Comorbidity Index (CIRS-CI): OR = 1.85; 95% CI = 1.03–3.32, C-Reactive phase Protein (CRP) OR = 3.73; 95% CI = 1.24–11.22, N-terminal-pro-Brain Natriuretic Peptide (NT-proBNP): OR = 2.39; 95% CI = 1.21–4.72 and Gal-3: OR = 5.64; 95% CI = 1.97–16.22 resulted in being significantly and independently associated with frailty. The DCA demonstrated that the addition of Gal-3 in the prognostic model resulted in an improved clinical ‘net’ benefit. Conclusions: Circulating levels of Gal-3 are independently associated with frailty in elderly patients with systolic HF. MDPI 2020-07-14 /pmc/articles/PMC7408835/ /pubmed/32674344 http://dx.doi.org/10.3390/jcm9072229 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Komici, Klara Gnemmi, Isabella Bencivenga, Leonardo Vitale, Dino Franco Rengo, Giuseppe Di Stefano, Antonino Eleuteri, Ermanno Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure |
title | Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure |
title_full | Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure |
title_fullStr | Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure |
title_full_unstemmed | Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure |
title_short | Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure |
title_sort | impact of galectin-3 circulating levels on frailty in elderly patients with systolic heart failure |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408835/ https://www.ncbi.nlm.nih.gov/pubmed/32674344 http://dx.doi.org/10.3390/jcm9072229 |
work_keys_str_mv | AT komiciklara impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure AT gnemmiisabella impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure AT bencivengaleonardo impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure AT vitaledinofranco impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure AT rengogiuseppe impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure AT distefanoantonino impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure AT eleuteriermanno impactofgalectin3circulatinglevelsonfrailtyinelderlypatientswithsystolicheartfailure |